Lantern Pharma Uses AI to Accelerate Cancer Drug Development | FintechTV Interview at the NYSE
Investors + biotech analysts: Lantern Pharma is pioneering AI-driven drug development — using large-scale machine learning to find new drugs, reposition existing molecules, and target precision oncology indications where unmet need is massive.
Lantern CEO Panna Sharma explains how their AI platform — which now self-learns, reads papers, models molecules, predicts patient response and suggests new indications — is compressing timelines and cost structures in drug development.
The company currently has three clinical-stage oncology candidates, including:
• A Phase 2 trial for non-smoker non-small cell lung cancer (a molecularly different disease than smoker NSCLC)
• A program for cancers with DNA damage repair deficiency, where their drug uses synthetic lethality and activates inside cancer cells only
Lantern expects to release upcoming clinical data milestones from its LP-184 program and others, and is also preparing the first major commercial rollout of its AI platform to drug developers worldwide.
Lantern believes we are entering the golden era of medicine — where AI, data and robotics will eventually produce customized drugs, faster development, lower cost, and more treatments than ever before.
Interview recorded at the New York Stock Exchange.
🔖 TAGS
#Investors #Biotech #LanternPharma #CancerResearch #AIinMedicine #PrecisionOncology #DrugDevelopment #ClinicalTrials #SyntheticLethality #FintechTV #NYSE #NonSmokerLungCancer #DNARepair #AI #MachineLearning #Pharmaceuticals #BiotechInvesting #HealthcareInnovation #FutureOfMedicine #CancerCure #DrugPipeline #AIPlatforms #Oncology #MedicalBreakthroughs
